Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 PR Newswire CUPERTINO, Calif., Jan. 27, 2011 CUPERTINO, Calif., Jan. 27, 2011 /PRNewswire/ -- DURECT...
Zacks Analyst Blog Highlights: Pfizer, King Pharmaceuticals, Durect Pharma, Pain Therapeutics and Acura Pharmaceuticals PR Newswire CHICAGO, Jan. 25, 2011 CHICAGO, Jan. 25, 2011 /PRNewswire/...
BRISTOL, Tenn. and SAN MATEO, Calif., Dec. 27, 2010 (GLOBE NEWSWIRE) -- King Pharmaceuticals®, Inc. (NYSE:KG) and Pain Therapeutics®, Inc. (Nasdaq:PTIE) today announced that King has resubmitted...
REMOXY® New Drug Application Resubmitted PR Newswire CUPERTINO, Calif., Dec. 27, 2010 CUPERTINO, Calif., Dec. 27, 2010 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported...
King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY® PR Newswire BRISTOL, Tenn. and SAN MATEO, Calif., Dec. 27, 2010 BRISTOL, Tenn. and SAN MATEO...
King Pharmaceuticals and Acura Pharmaceuticals Announce Submission of New Drug Application for ACUROX® Tablets PR Newswire BRISTOL, Tenn. and PALATINE, Ill., Dec. 20, 2010 BRISTOL, Tenn. and...
Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc. PR Newswire NEW YORK, Dec. 15, 2010 NEW YORK, Dec. 15, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced...
Standard & Poor's Announces Changes to U.S. Indices PR Newswire NEW YORK, Dec. 9, 2010 NEW YORK, Dec. 9, 2010 /PRNewswire/ -- S&P will make the following changes to the S&P 500, S&P MidCap 400...
Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc. PR Newswire NEW YORK, Oct. 22 NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today...
The Law Office of Abe Shainberg is investigating the Board of Directors of King Pharmaceuticals, Inc. (NYSE:KG) for possible breaches of fiduciary duty and other violations of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
